What is the history of Progressive multifocal leukoencephalopathy?

Progressive multifocal leukoencephalopathy (PML) was first described in 1958 as a rare, fatal demyelinating disease of the central nervous system occurring primarily in patients with underlying malignancy. Modern medicine has since identified the JC virus as the causative agent, transforming our understanding of Progressive multifocal leukoencephalopathy from a mysterious neurological decline into a condition linked to profound immune system suppression.

When and how was Progressive multifocal leukoencephalopathy first described?

The history of Progressive multifocal leukoencephalopathy began in 1958 when neurologists K.E. Åström, E.L. Mancall, and E.P. Richardson Jr. published a landmark paper in the journal Brain. They detailed three cases of patients suffering from chronic lymphocytic leukemia and Hodgkin’s disease who exhibited bizarre neurological symptoms. At the time, the etiology remained unknown, and the condition was characterized by the widespread destruction of myelin (the protective sheath surrounding nerve fibers) in the brain, which they termed "multifocal" due to the scattered nature of the lesions.

How has the understanding of the JC virus evolved?

For over a decade after the initial description, the cause of Progressive multifocal leukoencephalopathy remained a mystery. It was not until 1971 that researchers utilized electron microscopy to identify viral particles in the brain tissue of deceased patients. These particles were identified as polyomavirus, later named the "JC virus" after the initials of the patient (John Cunningham) from whom it was first isolated. We now know that the JC virus is widespread in the general population—up to 80% of adults carry it—but it remains dormant in healthy individuals, only causing Progressive multifocal leukoencephalopathy when the immune system becomes severely compromised.

What are the major milestones in the history of treatment?

The management of Progressive multifocal leukoencephalopathy has shifted from palliative care to immune modulation. Historically, there were no effective treatments. However, the medical community has reached several key milestones in addressing the disease:

• The HIV/AIDS Era: In the 1980s and 90s, the incidence of Progressive multifocal leukoencephalopathy surged alongside the AIDS epidemic, leading to intensive research into antiretroviral therapies that could restore immune function.


• Immune Reconstitution: The primary "treatment" today involves the withdrawal of immunosuppressive medications or the use of Highly Active Antiretroviral Therapy (HAART) to allow the patient's own immune system to suppress the JC virus.


• Clinical Trials: Modern research has explored various agents, such as pembrolizumab and interleukin-7, to "wake up" the immune system to fight the infection more effectively.

How have technology and patient advocacy changed the landscape?

Advanced diagnostic technology, specifically the development of Polymerase Chain Reaction (PCR) testing for cerebrospinal fluid, has revolutionized the identification of Progressive multifocal leukoencephalopathy. Previously, a brain biopsy was often required for a definitive diagnosis, which carried significant risks. Today, non-invasive testing allows for earlier diagnosis. Within the DiseaseMaps.org community, 16 individuals have connected to share their experiences, highlighting the shift toward patient-centered advocacy, where affected families now play a critical role in driving awareness for this rare condition.

Next steps

• Consult a neurologist or infectious disease specialist if you have concerns about neurological symptoms and immune health.


• Connect with the 16 members on DiseaseMaps.org to share your journey and learn from others living with this condition.


• Monitor updates on the National Institutes of Health (NIH) GARD website for the latest clinical trial opportunities.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Progressive multifocal leukoencephalopathy.


• Orphanet: Rare disease database entry for Progressive multifocal leukoencephalopathy.


• OMIM (Online Mendelian Inheritance in Man): Clinical synopsis of polyomavirus-associated disease.


• PubMed: "Progressive multifocal leukoencephalopathy: a 50-year perspective" (Åström, Mancall, and Richardson historical review).